About: Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs
Creator	Holbrook, Michael Jahrling, Peter Dyall, Julie Michelotti, Julia Zhou, Huanying Postnikova, Elena Hensley, Lisa Honko, Anna Cai, Yingyun Gross, Robin Olinger, Gene Logue, James Cong, Yu Deiuliis, Nicole Yu, Shuiqing Bennett, Richard Dewald, Lisa Hart, Brit
Source	PMC
abstract	Identifying effective antivirals for treating Ebola virus disease (EVD) and minimizing transmission of such disease is critical. A variety of cell-based assays have been developed for evaluating compounds for activity against Ebola virus. However, very few reports discuss the variable assay conditions that can affect the results obtained from these drug screens. Here, we describe variable conditions tested during the development of our cell-based drug screen assays designed to identify compounds with anti-Ebola virus activity using established cell lines and human primary cells. The effect of multiple assay readouts and variable assay conditions, including virus input, time of infection, and the cell passage number, were compared, and the impact on the effective concentration for 50% and/ or 90% inhibition (EC(50), EC(90)) was evaluated using the FDA-approved compound, toremifene citrate. In these studies, we show that altering cell-based assay conditions can have an impact on apparent drug potency as measured by the EC(50). These results further support the importance of developing standard operating procedures for generating reliable and reproducible in vitro data sets for potential antivirals.
has issue date	2018-03-22(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0194880
bibo:pmid	29566079
has license	cc0
sha1sum (hex)	30f8d46cca4f068ecc358d99115a885d458ad9b7
schema:url	https://doi.org/10.1371/journal.pone.0194880
resource representing a document's title	Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs
has PubMed Central identifier	PMC5864066
has PubMed identifier	29566079
schema:publication	PLoS One
resource representing a document's body	covid:30f8d46cca4f068ecc358d99115a885d458ad9b7#body_text
is schema:about of	named entity 'treating' named entity 'developed' named entity 'drug' named entity 'influence' named entity 'therapeutics' covid:arg/30f8d46cca4f068ecc358d99115a885d458ad9b7 named entity 'conditions' named entity 'evaluated' named entity 'Ebola virus' named entity 'data sets' named entity 'assay' named entity 'effective concentration' named entity 'human' named entity 'compounds' named entity 'compounds' named entity 'assays' named entity 'cell-based' named entity 'antivirals' named entity 'drug screen' named entity 'virus' named entity 'infection' named entity 'FDA' named entity 'drug screens' named entity 'potency' named entity 'standard operating procedures' named entity 'Ebola virus' named entity 'compound' named entity 'virus' named entity 'citrate' named entity 'cell lines' named entity 'Ebola virus disease' named entity 'effective concentration' named entity 'cell-based' named entity 'time' named entity 'Ebola' named entity 'passage number' named entity 'potency' named entity 'EVD' named entity 'cell-based assays' named entity 'cell-based assays' named entity 'antivirals' named entity 'toremifene' named entity 'measured' named entity 'assay' named entity 'minimizing' named entity 'infection' named entity 'assays' named entity 'citrate' named entity 'virus' named entity 'variable' named entity 'potency' named entity 'reliable' named entity 'generating' named entity 'cell lines' named entity 'development' named entity 'drug screen' named entity 'effective' named entity 'apparent' named entity 'variable' named entity 'antivirals' named entity 'potential' named entity 'variable' named entity 'cells' named entity 'toremifene'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software